Articles related to PANCREATIC CANCER

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.

A patient with obstructive jaundice and persistent suspicion for periampullary malignancy was ultimately found to have multifocal grade 1 pancreatic neuroendocrine tumors after surgical resection. The case highlights the diagnostic limitations of preoperative tissue sampling in selected periampullary lesions.

A phase 1 study of mKRAS-VAX in 20 patients at high risk for PDAC showed KRAS-specific T-cell responses in most participants. No high-grade adverse events occurred, but clinical prevention data remain early.

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.

A high-sensitivity KRAS-targeted blood test detects residual pancreatic cancer missed by standard assays, suggesting current monitoring approaches may underestimate recurrence risk despite treatment.

Daraxonrasib, an oral RAS(ON) inhibitor, doubled overall survival and progression-free survival versus chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma across RAS-mutated and wild-type disease in a phase 3 trial.